This HTML5 document contains 49 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/domain/vavai/projekt/
n9http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n18http://linked.opendata.cz/ontology/domain/vavai/
n13http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F67985904%3A_____%2F00%3A21003033%21RIV%2F2003%2FAV0%2FA21003%2FN/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n5http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F67985904%3A_____%2F00%3A21003033%21RIV%2F2003%2FAV0%2FA21003%2FN
rdf:type
skos:Concept n18:Vysledek
dcterms:description
Background. Bovine seminal ribonuclease (BS-RNase) exerts selective cytotoxicity toward different types of tumor cells. In the present study, we tested the effects of BS-RNase on cultured neuroblastoma (NB) cells resistant to chemotherapeutic agents. The selectivity of the antitumoral activity of BS-RNase was evaluated using cultures of CD34(+) hematopoietic stem cells. Materials and Methods Human NE cell lines including IMR-32, UKF-NB-2 and UKF-NB-3 were selected for resistance against vincristine, doxorubicin or cisplatin by exposure to increasing concentrations of the respective drug. The cytotoxicity of the drugs to NE cells was evaluated using a clonogenic assay in a methylcellulose medium. Peripheral blood progenitor cells were obtained from adult healthy donors by positive selection using specific anti-CD34(+) antibodies. The toxicity of BS-RNase to CD34(+) cells was assessed in the direct clonogenic assay using methylcellulose medium of in ex vivo expansion culture supplemented with hematopoie Background. Bovine seminal ribonuclease (BS-RNase) exerts selective cytotoxicity toward different types of tumor cells. In the present study, we tested the effects of BS-RNase on cultured neuroblastoma (NB) cells resistant to chemotherapeutic agents. The selectivity of the antitumoral activity of BS-RNase was evaluated using cultures of CD34(+) hematopoietic stem cells. Materials and Methods Human NE cell lines including IMR-32, UKF-NB-2 and UKF-NB-3 were selected for resistance against vincristine, doxorubicin or cisplatin by exposure to increasing concentrations of the respective drug. The cytotoxicity of the drugs to NE cells was evaluated using a clonogenic assay in a methylcellulose medium. Peripheral blood progenitor cells were obtained from adult healthy donors by positive selection using specific anti-CD34(+) antibodies. The toxicity of BS-RNase to CD34(+) cells was assessed in the direct clonogenic assay using methylcellulose medium of in ex vivo expansion culture supplemented with hematopoie
dcterms:title
Bovine seminal ribonuclease exerts selective cytotoxicity toward neuroblastoma cells both sensitive and resistant to chemotherapeutic drugs. Bovine seminal ribonuclease exerts selective cytotoxicity toward neuroblastoma cells both sensitive and resistant to chemotherapeutic drugs.
skos:prefLabel
Bovine seminal ribonuclease exerts selective cytotoxicity toward neuroblastoma cells both sensitive and resistant to chemotherapeutic drugs. Bovine seminal ribonuclease exerts selective cytotoxicity toward neuroblastoma cells both sensitive and resistant to chemotherapeutic drugs.
skos:notation
RIV/67985904:_____/00:21003033!RIV/2003/AV0/A21003/N
n3:strany
853;860
n3:aktivita
n7:Z n7:P
n3:aktivity
P(GA523/96/1738), P(KSK2038602), P(KSK2052601), Z(AV0Z5045916)
n3:cisloPeriodika
N/A
n3:dodaniDat
n5:2003
n3:domaciTvurceVysledku
n9:5105153
n3:druhVysledku
n12:J
n3:duvernostUdaju
n6:S
n3:entitaPredkladatele
n8:predkladatel
n3:idSjednocenehoVysledku
705890
n3:idVysledku
RIV/67985904:_____/00:21003033
n3:jazykVysledku
n16:eng
n3:klicovaSlova
N/A
n3:klicoveSlovo
n4:N%2FA
n3:kodStatuVydavatele
GR - Řecká republika
n3:kontrolniKodProRIV
[9A67EDE5754C]
n3:nazevZdroje
Anticancer Research
n3:obor
n14:EB
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
9
n3:pocetUcastnikuAkce
0
n3:pocetZahranicnichUcastnikuAkce
0
n3:projekt
n17:GA523%2F96%2F1738 n17:KSK2038602 n17:KSK2052601
n3:rokUplatneniVysledku
n5:2000
n3:svazekPeriodika
20
n3:tvurceVysledku
Schwabe, D. Činátl, J. jr. Woodcock, B. G. Vogel, J.-U. Kotchetkov, R. Koehl, U. Činátl, J. Matoušek, Josef Kornhuber, B.
n3:zamer
n13:AV0Z5045916
s:issn
0250-7005
s:numberOfPages
8